ProNAi Therapeutics, Inc. (NASDAQ:DNAI), Amongst Others, Under Investigation

ProNAi Therapeutics, Inc. (NASDAQ:DNAI), along with Cognizant Technology Solutions Corporation, BofI Holding, Inc, Seres Therapeutics, Inc., SeaWorld Entertainment, Inc. are under investigation by shareholder rights law firm Johnson & Weaver, LLP.

SAN DIEGO, Oct. 3, 2016 /PRNewswire/ — Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Cognizant Technology Solutions Corporation, BofI Holding, Inc, Seres Therapeutics, Inc., SeaWorld Entertainment, Inc., and ProNAi Therapeutics, Inc., as detailed below.

Johnson & Weaver, LLP, is investigating potential violations of the federal securities laws by Cognizant Technology Solutions Corporation (CTSH) and certain of its officers. On September 30, 2016, Cognizant made known that it was conducting an internal investigation into whether certain payments in India violated the U.S. Foreign Corrupt Practices Act. Cognizant also announced that its president had resigned. On this news, shares of Cognizant closed down sharply on September 30, 2016.

If you have information that could assist in this investigation, including past employees and others, or if you are a Cognizant shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

Johnson & Weaver, LLP is investigating potential violations of federal and state  laws by BofI Holding, Inc. (BOFI) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased BofI stock between September 4, 2013 through October 13, 2015, (the “Class Period”).

According to the complaint, Defendants made false and misleading statements and failed to disclose that: (1) BofI’s internal controls were frequently disregarded; (2) BofI’s borrowers included foreign nationals who should have been off-limits under federal anti-money-laundering laws; (3) many BofI accounts lacked required tax identification numbers; (4) BofI fired an internal auditor who raised these issues to management and to federal regulators; and (5) as a result of the above, BofI’s statements regarding its internal controls and other financial statements were materially false and misleading at all relevant times.

If you have held BofI shares continuously prior to September 4, 2013, you may have standing to hold BofI harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing.

If you are a BofI shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

Seres Therapeutics, Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Seres Therapeutics, Inc. (MCRB) and certain of its officers. On July 29, 2016 Seres announced that its 8-week results from the ongoing SER-109 Phase 2 ECOSPOR™ clinical study for the prevention of multiply recurrent Clostridium difficile infection (“CDI”) did not meet the primary endpoint of reducing the relative risk of CDI recurrence. On this news, the price of Seres’ stock plummeted 69%.  Two days before the announcement, on July 27, 2016, Seres’ President, Chief Executive Officer, and Chairman of the Board (Roger Pomerantz) sold 20,000 shares at much higher prices.  Another senior executive, on that same day, sold 38,064 shares at $35.1285 per share for gross proceeds of $1,337,510.

Original Source

pronai-therapeutics-graph

Shares of ProNAi Therapeutics, Inc. (NASDAQ:DNAI) are actively moving +2.21% thus far today on the news and have traded in the range of $1.80 – 1.93 during the session.  A number of research firms have recently weighed in on the stock, providing future price targets. The covering firms currently have a consensus one-year price target of $2.50 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  This is the average number from the individual targets provided by the firms.  Analysts are projecting earnings per share of $-0.25 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-1.32 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading -0.29% away from its 50-day moving average of $1.86.  Based on the most recent available data, the equity is -91.13% off of its 52-week high of $20.85 and +4.52% away from its 52-week low which is $1.77.

Are Shares of ProNAi Therapeutics, Inc. (NASDAQ:DNAI) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Today, the stock opened at $1.82 and the last bid at the time of writing stood at $1.85.  During the session thus far, the equity dipped down to $1.80 and touched $1.93 as the high point.  ProNAi Therapeutics, Inc. (NASDAQ:DNAI) has a market cap of $56.10M and has seen an average daily volume of 722306 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment